Stock Events

Stock Events

Kalaris Therapeutics 

$4.02
23
-$0.15-3.6% 15:47 Today

Statistics

Day High
4.2
Day Low
3.97
52W High
11.88
52W Low
2.37
Volume
6,149
Avg. Volume
261,840
Mkt Cap
95.7M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-7.34
-5.04
-2.75
-0.46
Expected EPS
-0.52125
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-43.44MNet Income

Analyst Ratings

18.67Average Price Target
The highest estimate is 25.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences is a biopharmaceutical company that competes with AlloVir in the development of antiviral drugs, including treatments for viral infections which is a direct competition to AlloVir's focus on viral diseases.
Moderna
MRNA
Mkt Cap25.28B
Moderna is involved in the development of mRNA-based therapies and vaccines for infectious diseases, competing with AlloVir's viral infection treatments.
BioNTech
BNTX
Mkt Cap23.38B
BioNTech competes in the space of developing treatments and vaccines for infectious diseases, directly competing with AlloVir's focus area.
Novavax
NVAX
Mkt Cap1.33B
Novavax is a competitor due to its focus on developing vaccines for infectious diseases, including COVID-19, which puts it in direct competition with AlloVir's infectious disease portfolio.
Pfizer
PFE
Mkt Cap152.69B
Pfizer develops and markets drugs and vaccines for a wide range of infectious diseases, competing with AlloVir in the infectious disease market.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its pharmaceutical division Janssen, develops treatments and vaccines for infectious diseases, competing with AlloVir's product pipeline.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals competes with AlloVir in developing monoclonal antibodies for the treatment of viral infections and other diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals is involved in the development of treatments for viral diseases, among other areas, which puts it in competition with AlloVir.
Arbutus Biopharma
ABUS
Mkt Cap923.95M
Arbutus Biopharma is focused on discovering and developing antiviral therapies, making it a direct competitor to AlloVir in the antiviral space.

About

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Show more...
CEO
Andrew Oxtoby
Employees
20
Country
United States
ISIN
US4829291065

Listings

XNAS
US
KLRS
BOATS
BOATS
KLRS.BOATS

0 Comments

Share your thoughts

FAQ

What is Kalaris Therapeutics stock price today?▼
The current price of KLRS is $4.02 USD — it has decreased by -3.6% in the past 24 hours. Watch Kalaris Therapeutics stock price performance more closely on the chart.
What is Kalaris Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Kalaris Therapeutics stocks are traded under the ticker KLRS.
Is Kalaris Therapeutics stock price growing?▼
KLRS stock has risen by +5.41% compared to the previous week, the month change is a +2.25% rise, over the last year Kalaris Therapeutics has showed a +59.14% increase.
What is Kalaris Therapeutics market cap?▼
Today Kalaris Therapeutics has the market capitalization of 95.7M
When is the next Kalaris Therapeutics earnings date?▼
Kalaris Therapeutics is going to release the next earnings report on November 18, 2026.
What were Kalaris Therapeutics earnings last quarter?▼
KLRS earnings for the last quarter are -0.48 USD per share, whereas the estimation was -0.5 USD resulting in a +3.03% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Kalaris Therapeutics revenue for the last year?▼
Kalaris Therapeutics revenue for the last year amounts to 0 USD.
What is Kalaris Therapeutics net income for the last year?▼
KLRS net income for the last year is -43.44M USD.
How many employees does Kalaris Therapeutics have?▼
As of August 20, 2026, the company has 20 employees.
In which sector is Kalaris Therapeutics located?▼
Kalaris Therapeutics operates in the Health & Wellness sector.
When did Kalaris Therapeutics complete a stock split?▼
The last stock split for Kalaris Therapeutics was on January 16, 2025 with a ratio of 1:23.
Where is Kalaris Therapeutics headquartered?▼
Kalaris Therapeutics is headquartered in BERKELEY HEIGHTS, United States.